Assessment of hydration by means of bioelectrical impedance and arm muscle area during growth hormone (GH) replacement therapy: A prospective study of 130 GH-deficient patients

Badre-Esfahani, Sara; Nellemann, Birgitte; Danielsen, Ditte H.; Fisker, Sanne; Christiansen, Jens Sandahl; Jørgensen, Jens Otto Lunde

doi:10.1016/j.ghir.2007.01.012

Cited by 2 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Symptoms of GH deficiency in adults include central obesity, reduced muscle mass and poor quality of life, unfavorable blood lipids as well as increased glucose levels [ 8 , 9 , 10 ]. Moreover, GH deficiency is associated with dehydration [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Copeptin in Growth Hormone-Treated Patients

Sjöström

Chisalita

Höybye

2022

JCM

View full text Add to dashboard Cite

Growth hormone (GH) changes body composition, including increasing body water. GH is known to have an anti-natriuretic effect in the kidney, but little is known of its effect on arginine-vasopressin (AVP) release. We studied the effect of GH on AVP release by measurement of copeptin, a fragment from the same precursor protein, in GH-treated patients with GH deficiency. The study was designed as a retrospective cohort study of biobank samples from 34 patients substituted with GH between 1999 and 2004. Copeptin and insulin-like growth factor 1 (IGF-1) results were compared with previously obtained data. An increase in IGF-1 and copeptin was seen at 3 and 6 months' treatment compared to baseline. Between the 3 and 6 months follow up, copeptin levels were stable. There was a difference in HbA1c between 3 and 6 months (p < 0.01) and between baseline and 6 months (p = 0.042), with higher levels at 6 months. In addition, LDL levels were lower at the 6 months follow up (p = 0.046). The waist circumference at 3 months was lower (p = 0.02). To conclude, three months of GH treatment increased the levels of copeptin and the increase remained at 6 months. This could be a compensatory mechanism balancing the anti-natriuretic effect of GH treatment seen in previous studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Copeptin in Growth Hormone-Treated Patients

Sjöström

Chisalita

Höybye

2022

JCM

View full text Add to dashboard Cite

show abstract

Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline

Molitch

Clemmons

Malozowski

et al. 2011

The Journal of Clinical Endocrinology & Metabolism

727

464

View full text Add to dashboard Cite

GHD can persist from childhood or be newly acquired. Confirmation through stimulation testing is usually required unless there is a proven genetic/structural lesion persistent from childhood. GH therapy offers benefits in body composition, exercise capacity, skeletal integrity, and quality of life measures and is most likely to benefit those patients who have more severe GHD. The risks associated with GH treatment are low. GH dosing regimens should be individualized. The final decision to treat adults with GHD requires thoughtful clinical judgment with a careful evaluation of the benefits and risks specific to the individual.

show abstract

Assessment of hydration by means of bioelectrical impedance and arm muscle area during growth hormone (GH) replacement therapy: A prospective study of 130 GH-deficient patients

Cited by 2 publications

References 17 publications

Copeptin in Growth Hormone-Treated Patients

Copeptin in Growth Hormone-Treated Patients

Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline

Contact Info

Product

Resources

About